Psychedelic Therapy & Integration

I provide a safe, non-judgmental space for psychedelic-assisted psychotherapy and psychedelic integration for clients in Columbus, Ohio.

“It’s a self treatment. It’s a treatment about who I am.

These are parts of my life that happen to involve trauma… but it’s not a trauma treatment. It’s a mind-expanding treatment.  We all are suffering human beings, we have all had major disappointments, we have had hurt, we have had pain in our lives, some more than others. But we’re dealing, really, with the human condition.

– Bessel van Der Kolk


Psychedelic Integration

Psychedelic integration therapy is a form of holistic therapy that processes an individual’s own, self-guided or retreat experiences with plant medicines and psychedelics such as ayahuasca, psilocybin, or LSD. The goal of therapy is to help people process and integrate insights — sometimes from very difficult psychedelic experiences — into their daily lives, in order to improve their emotional well-being.


Ketamine Assisted Psychotherapy

Ketamine assisted psychotherapy (KAP) is currently the only legal form of psychedelic therapy available in Ohio, and is increasingly used for various chronic and treatment-resistant issues like depression, anxiety, OCD, PTSD, often after other treatment approaches have been unsuccessful. 

 The current state of

Psychedelic-Assisted Psychotherapy

Psychedelic-assisted psychotherapy is a form of therapy that involves the use of altered states of consciousness produced by psychedelic substances such as ketamine, LSD, psilocybin, or MDMA, or non-ordinary states of consciousness induced by breathwork, meditation, or other practices. 

In combination with therapy, individuals may address a variety of mental health issues, including depression, anxiety, PTSD and trauma-related disorders, and addiction. The goal of the therapy is to facilitate whole-self healing by helping individuals access deep-seated emotional material and gain new perspectives on their experiences. This approach has shown promise in clinical trials and is currently being studied in more detail.

Research and clinical trials are ongoing to study the safety and efficacy of psychedelics in treating various mental health conditions such as PTSD, depression, and anxiety. Although the use of psychedelics in therapy is not widely accepted or available due to legal regulations, the laws on psychedelics are rapidly changing and evolving. Currently, ketamine assisted psychotherapy is the only legal option for psychedelic assisted psychotherapy in Ohio, and most of the United States.

It is my intention to continue furthering education, training, and experience to offer additional options for psychedelic-assisted psychotherapy to clients in Ohio, once these options are legal and demonstrated as effective tools when used in combination with therapy.


Ketamine is a dissociative anesthetic, known for its use as an anesthetic for medical procedures, but increasingly used in lower, psychedelic doses in treatment of mental health conditions such as depression, anxiety, and PTSD.

Renewed interest and studies over the past decade demonstrate that ketamine combined with therapy may assist clinical populations whose symptoms and psychological issues are treatment-resistant, or have not been responsive to treatment by other means. Ketamine assisted psychotherapy (KAP) holds promise for effective treatment of individuals with various types and severity of symptoms and issues.

Ketamine is currently the only legal option for use with psychotherapy in Ohio, and is increasingly used for various chronic and treatment-resistant issues like depression, anxiety, OCD, and PTSD.


MDMA (3,4-methylenedioxy-methamphetamine) is a potent empathogen–entactogen. MAPS (Multidisciplinary Association for Psychedelic Studies) is an organization that conducts research on the medical and therapeutic potential of psychedelics, and has been conducting clinical trials on the use of MDMA for the treatment of post-traumatic stress disorder (PTSD). The therapy has shown promising results, offering a significant reduction in PTSD symptoms among the participants who received MDMA-assisted therapy compared to those who received placebo.

As of January 2024, the FDA has accepted the new drug application for MDMA-AT, granting priority review with a target action date of August 11th, 2024.

In Ohio, MDMA is not yet available for legal, therapeutic use outside of the clinical trials, although this is expected to change by the end of 2024.


Psilocybin, a psychedelic compound found in certain mushrooms (i.e. “magic mushrooms”), has been the subject of a growing number of clinical trials in recent years to study its potential therapeutic benefits for end-of-life concerns, depression, and addictions.

In 2020, the FDA granted “Breakthrough Therapy” designation to psilocybin therapy for treatment-resistant depression. This means that the FDA recognizes the potential for psilocybin to be a significant improvement over existing therapies and will expedite the development and review of the therapy.

It’s important to note that while the results from these clinical trials are promising, more research is needed before psilocybin can be approved as a treatment for these conditions.

In Ohio, psilocybin is not yet available for legal, therapeutic use outside of clinical trials, although other cities and states have decriminalized or legalized possession and/or use.

Let's stay in touch.

I am not currently accepting new clients for individual psychotherapy, couples therapy, or ketamine-assisted psychotherapy work. However, I am offering group psychedelic-asssisted psychotherapy programs with LuminaThera.

If you’d like to get practice updates including notifications when I am accepting new clients, please sign up for emails. I don’t send out recurring email blasts and promise to be respectful of your inbox!